Actinium Pharmaceuticals Announces Initiation of Actimab-A Triplet Combination Frontline Trial Under NCI CRADA with Venetoclax and Taiho Oncology's Hypomethylating Agent ASTX-727 in Patients with Newly Diagnosed AML
Portfolio Pulse from
Actinium Pharmaceuticals has initiated a clinical trial for a new triplet combination therapy for AML, involving Actimab-A, Venetoclax, and ASTX-727. This trial, under a CRADA with the NCI, marks the first use of targeted radiotherapy as a backbone in such a combination.
March 11, 2025 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Actinium Pharmaceuticals has initiated a trial for a new AML therapy combining Actimab-A, Venetoclax, and ASTX-727. This expands their potential market and showcases their innovation in targeted radiotherapy.
The initiation of this trial represents a significant step for Actinium Pharmaceuticals, as it expands their market potential in AML treatment. The use of targeted radiotherapy as a backbone therapy is innovative and could lead to positive clinical outcomes, boosting investor confidence.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100